NEFL and COVID-19: Notably, the first clinical hydroxyl-dendrimer conjugate showed positive results in a recent Phase II COVID-19 trial (NCT04458298), where it significantly reduced the plasma levels of the neuroinflammatory cytokine Neurofilament light chain (NfL), and improved survival rates in severely impaired hospitalized patients [61].